易瑞沙 耐药后的解决方案，请大家都来找出路

东方

以上信息相信对正在寻求易瑞沙耐药后方案的医生来说也提供了相当的帮助，期望类似的结果更多，早日找到后易瑞沙时期的最佳治疗方法。

救父涂存

<p><p><font size="4"></font></p><font size="4">我爸爸这两天舌头下面（舌弦）溃疡，疼的厉害。因为前不久口腔溃疡很久才好，又马上舌下溃疡，爸爸说他是火气太重，或者是缺少维生素。不知道大家的家长是不是也有这样的情况，还是吃易瑞莎的副作用？还是印度版易瑞莎的副作用？</font></p><p><font size="4">另外，昨天看了一篇文章，提到的内容是，吃易瑞莎的副反应越大，药物有效期越长，耐药越晚到来，不知道是不是真的？</font></p>

为了我的母亲

试试？/

妈妈健康

<p>这个药是火气比较大,我妈还长了治疮</p><p></p>

jimmy112199

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">Re-treatment with gefitinib in advanced lung adenocarcinoma
patients: a<span>&#160; </span>retrospective analysis <op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">Takashi Kasai<span>&#160; </span>1<span>&#160; </span>, Hiroshi Soda<span>&#160; </span>2<span>&#160; </span>,
Hiroshi Takatani<span>&#160; </span>3<span>&#160; </span>, Minoru Fukuda<span>&#160; </span>4<span>&#160; </span>,
Reiji Nakano<span>&#160; </span>3<span>&#160; </span>,<span>&#160;
</span>Akitoshi Kinoshita<span>&#160; </span>3<span>&#160; </span>, Masaaki Fukuda<span>&#160; </span>3<span>&#160; </span>,
Seiji Nagashima<span>&#160; </span>3<span>&#160; </span>, Yoichi Nakamura<span>&#160; </span>2<span>&#160; </span>,
Yoshifumi Soejima<span>&#160; </span>3<span>&#160; </span>,<span>&#160;
</span>Mikio Oka<span>&#160; </span>4<span>&#160; </span>, Shigeru Kohno<span>&#160; </span>2<span>&#160; </span><op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">1<span>&#160; </span></span><st1place><st1placename><span style="font-family: &quot;MS Mincho&quot;;">Isahaya</span></st1placename><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placename><span style="font-family: &quot;MS Mincho&quot;;">General</span></st1placename><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placetype><span style="font-family: &quot;MS Mincho&quot;;">Hospital</span></st1placetype></st1place><span style="font-family: &quot;MS Mincho&quot;;">, </span><st1place><st1city><span style="font-family: &quot;MS Mincho&quot;;">Nagasaki</span></st1city><span style="font-family: &quot;MS Mincho&quot;;">, </span><st1country-region><span style="font-family: &quot;MS Mincho&quot;;">Japan</span></st1country-region></st1place><span style="font-family: &quot;MS Mincho&quot;;"><span>&#160; </span><op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">2<span>&#160; </span></span><st1place><st1placename><span style="font-family: &quot;MS Mincho&quot;;">Nagasaki</span></st1placename><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placetype><span style="font-family: &quot;MS Mincho&quot;;">University</span></st1placetype><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placetype><span style="font-family: &quot;MS Mincho&quot;;">School</span></st1placetype></st1place><span style="font-family: &quot;MS Mincho&quot;;"> of
Medicine<span>&#160; </span><op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">3<span>&#160; </span></span><st1city><st1place><span style="font-family: &quot;MS Mincho&quot;;">Nagasaki</span></st1place></st1city><span style="font-family: &quot;MS Mincho&quot;;"> Thoracic
Oncology Group <op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">4<span>&#160; </span></span><st1place><st1placename><span style="font-family: &quot;MS Mincho&quot;;">Kawasaki</span></st1placename><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placename><span style="font-family: &quot;MS Mincho&quot;;">Medical</span></st1placename><span style="font-family: &quot;MS Mincho&quot;;">
                        </span><st1placetype><span style="font-family: &quot;MS Mincho&quot;;">School</span></st1placetype></st1place><span style="font-family: &quot;MS Mincho&quot;;"><span>&#160; </span><op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">Background: Gefitinib is a selective EGFR tyrosine kinase
inhibitor, and has the anti-tumor activity for lung<span>&#160; </span>cancer. Recently, there are a few reports
about the efficacy of re-treatment with gefitinib in lung cancer<span>&#160; </span>patients. Methods: We retrospectively analyzed
patients with advanced lung adenocarcinoma, who received re-<span>&#160; </span>treatment with gefitinib in NTOG hospitals.
We informed patients about predictive effects and adverse events<span>&#160; </span>of this re-treatment. Results: A total of
eight patients with stage IV disease were analyzed. The patients<span>&#160; </span>characteristics were as follows; median age
(range) = 63 (49-80), male/female = 2/6, PS0/1/2/3/4 = 0/4/1/2/1,<span>&#160; </span>smoker/non-smoker = 2/6. First line gefitinib
treatment showed the effectiveness in seven and no response in<span>&#160; </span>another one. The reasons of discontinue of
first line gefitinib therapy were liver dysfunction in two and tumor<span>&#160; </span>progression in another six. Re-treatment with
gefitinib showed the efficacy in six and disease progression in<span>&#160; </span>two. In six responders by re-treatment, five
patients had tumor progression after the first line therapy. These<span>&#160; </span>five patients were male/female = 1/4,
smoker/non-smoker = 1/4. Mild tumor reduction and improve of<span>&#160; </span>symptom were achieved in three and decrease
of CEA levels in two of these five patients. Conclusions: Re-<span>&#160; </span>treatment with gefitinib may have the
efficacy to selected patients with gefitinib resistant lung<span>&#160; </span>adenocarcinoma<op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;"><op>&#160;</op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">重</span>
                <span style="font-family: &quot;MS Mincho&quot;;">新使用</span>iressa<span style="font-family: &quot;MS Mincho&quot;;">治</span><span style="font-family: PMingLiU;">疗晚期肺腺癌患者的回顾分析</span>:</p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">Takashi Kasai<span>&#160; </span>1<span>&#160; </span>, Hiroshi Soda<span>&#160; </span>2<span>&#160; </span>,
Hiroshi Takatani<span>&#160; </span>3<span>&#160; </span>, Minoru Fukuda<span>&#160; </span>4<span>&#160; </span>,
Reiji Nakano<span>&#160; </span>3<span>&#160; </span>,<span>&#160;
</span>Akitoshi Kinoshita<span>&#160; </span>3<span>&#160; </span>, Masaaki Fukuda<span>&#160; </span>3<span>&#160; </span>,
Seiji Nagashima<span>&#160; </span>3<span>&#160; </span>, Yoichi Nakamura<span>&#160; </span>2<span>&#160; </span>,
Yoshifumi Soejima<span>&#160; </span>3<span>&#160; </span>,<span>&#160;
</span>Mikio Oka<span>&#160; </span>4<span>&#160; </span>, Shigeru Kohno<span>&#160; </span>2<span>&#160; </span><op></op></span></p>

<p class="MsoNormal">1<span style="font-family: PMingLiU;">谏早总医院</span>, <span style="font-family: PMingLiU;">长崎</span>,<span style="font-family: &quot;MS Mincho&quot;;"> 日本</span><span style="font-family: PMingLiU;"><op></op></span></p>

<p class="MsoNormal">2<span style="font-family: &quot;MS Mincho&quot;;">日本</span><span style="font-family: PMingLiU;">长崎大学医学院，长崎胸部肿瘤组<op></op></span></p>

<p class="MsoNormal">4<span style="font-family: PMingLiU;">长</span><span style="font-family: &quot;MS Mincho&quot;;">崎医学院<op></op></span></p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">背景<op></op></span></p>

<p class="MsoNormal">iressa<span style="font-family: &quot;MS Mincho&quot;;">是一</span><span style="font-family: PMingLiU;">种选择性</span>EGFR<span style="font-family: &quot;MS Mincho&quot;;">酪氨酸激</span><span style="font-family: Batang;">酶抑制</span><span style="font-family: PMingLiU;">剂</span>,<span style="font-family: &quot;MS Mincho&quot;;">并具有抗</span><span style="font-family: PMingLiU;">肿瘤活性</span>,<span style="font-family: PMingLiU;">为肺癌</span>. <span style="font-family: &quot;MS Mincho&quot;;">最近</span>,<span style="font-family: &quot;MS Mincho&quot;;">有一些</span><span style="font-family: PMingLiU;">报道了</span><span style="font-family: &quot;MS Mincho&quot;;">重</span>
                <span style="font-family: &quot;MS Mincho&quot;;">新使用</span>iressa<span style="font-family: &quot;MS Mincho&quot;;"></span><span style="font-family: &quot;MS Mincho&quot;;">治</span><span style="font-family: PMingLiU;">疗肺癌患者疗效</span>.</p>

<p class="MsoNormal"><span>&#160;</span><span style="font-family: &quot;MS Mincho&quot;;">方法</span>:</p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">回</span><span style="font-family: PMingLiU;">顾分析，</span>12<span style="font-family: &quot;MS Mincho&quot;;">例中</span><span style="font-family: PMingLiU;">晚期肺腺癌</span>,<span style="font-family: &quot;MS Mincho&quot;;">他</span><span style="font-family: PMingLiU;">们接到</span><span style="font-family: &quot;MS Mincho&quot;;">重</span>
                <span style="font-family: &quot;MS Mincho&quot;;">新使用</span>iressa<span style="font-family: &quot;MS Mincho&quot;;"></span><span style="font-family: &quot;MS Mincho&quot;;">的治</span><span style="font-family: PMingLiU;">疗，在NTOG</span><span style="font-size: 10pt;">
                </span><span style="font-family: &quot;MS Mincho&quot;;">医院</span>. <span style="font-family: &quot;MS Mincho&quot;;">我</span><span style="font-family: PMingLiU;">们告诉病人</span><span style="font-family: &quot;MS Mincho&quot;;">重</span>
                <span style="font-family: &quot;MS Mincho&quot;;">新使用iressa的</span><span style="font-family: PMingLiU;">预测疗效和不良后果</span>. <span style="font-family: PMingLiU;">结果</span>:</p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">一共有八个第四期患者</span><span style="font-family: PMingLiU;">进行了分析</span>. <span style="font-family: &quot;MS Mincho&quot;;">病人的特点如下</span>; <span style="font-family: &quot;MS Mincho&quot;;">年</span><span style="font-family: PMingLiU;">龄中位数</span>(<span style="font-family: &quot;MS Mincho&quot;;">范</span><span style="font-family: PMingLiU;">围</span>) = 63 ( 1949<span style="font-family: &quot;MS Mincho&quot;;">年至</span>1980<span style="font-family: &quot;MS Mincho&quot;;">年</span>) ,<span style="font-family: &quot;MS Mincho&quot;;">男</span>/<span style="font-family: &quot;MS Mincho&quot;;">女</span>= 2 / 6 , <span style="font-family: &quot;MS Mincho&quot;;">S</span> 0/1/2/3/4 = 0/4/1/2/1 , <span style="font-family: &quot;MS Mincho&quot;;">抽烟</span>/<span style="font-family: &quot;MS Mincho&quot;;">不抽烟</span>= 2 / 6 . <span style="font-family: &quot;MS Mincho&quot;;">第一</span><span style="font-family: PMingLiU;">线治疗显示七患者</span><span style="font-family: &quot;MS Mincho&quot;;">有</span><span style="font-family: PMingLiU;">效果</span>, ,<span style="font-family: &quot;MS Mincho&quot;;">在另一</span><span style="font-family: PMingLiU;">患者</span><span style="font-family: &quot;MS Mincho&quot;;">没有反</span><span style="font-family: PMingLiU;">应</span>.</p>

<p class="MsoNormal"><span style="font-family: &quot;MS Mincho&quot;;">停止一</span><span style="font-family: PMingLiU;">线治疗</span><span style="font-family: &quot;MS Mincho&quot;;">原因，两人</span><span style="font-family: PMingLiU;">肝功能不正常</span>,<span style="font-family: PMingLiU;">另外</span>6<span style="font-family: &quot;MS Mincho&quot;;">人</span><span style="font-family: PMingLiU;">癌进展</span>. <span style="font-family: &quot;MS Mincho&quot;;">重新使用IRESSA在六个病人</span><span style="font-family: PMingLiU;">显</span><span style="font-family: &quot;MS Mincho&quot;;">示效果，</span><span style="font-family: PMingLiU;">另外两</span><span style="font-family: &quot;MS Mincho&quot;;">人</span><span style="font-family: PMingLiU;">癌进展</span>. <span style="font-family: &quot;MS Mincho&quot;;">在六个有反</span><span style="font-family: MingLiU;">应的</span><span style="font-family: &quot;MS Mincho&quot;;">病人中</span>, <span style="font-family: &quot;MS Mincho&quot;;">其中</span>5<span style="font-family: &quot;MS Mincho&quot;;">例是</span><span style="font-family: PMingLiU;">第一线治疗肿瘤有效后又进展的</span>. <span style="font-family: PMingLiU;">这</span>5<span style="font-family: &quot;MS Mincho&quot;;">例中</span>,<span style="font-family: &quot;MS Mincho&quot;;">男</span>/<span style="font-family: &quot;MS Mincho&quot;;">女</span>= 1 / 4 ,<span style="font-family: &quot;MS Mincho&quot;;">抽烟</span>/<span style="font-family: &quot;MS Mincho&quot;;">不抽烟</span>= 1 / 4, 5<span style="font-family: &quot;MS Mincho&quot;;">人中，</span><span style="font-family: PMingLiU;">三个取得了</span>
                <span style="font-family: PMingLiU;">轻度肿瘤减小和改善症状，</span>
                <span style="font-family: &quot;MS Mincho&quot;;">两艘</span>CEA<span style="font-family: &quot;MS Mincho&quot;;">水平</span><span style="font-family: PMingLiU;">下降。<op></op></span></p>

<p class="MsoNormal"><span style="font-family: PMingLiU;">结论<op></op></span></p>

<span style="font-size: 12pt; font-family: PMingLiU;">对选定的对IRESSA抗药的肺腺癌患者，</span><span style="font-size: 12pt; font-family: &quot;MS Mincho&quot;;">重</span><span style="font-size: 12pt; font-family: &quot;Times New Roman&quot;;">
        </span><span style="font-size: 12pt; font-family: &quot;MS Mincho&quot;;">新使用</span><span style="font-size: 12pt; font-family: &quot;Times New Roman&quot;;">Gefitinib</span><span style="font-size: 12pt; font-family: PMingLiU;">可以有</span>

tkmtt

<p>TO:救父涂存</p><p><font size="4">你说的“吃易瑞莎的副反应越大，药物有效期越长，耐药越晚到来”我怎么听说是副反应越不明显耐药越晚？</font></p>[em06][em06]

〓大兔子〓

<p>to<strong><font face="Verdana" color="#da2549">救父涂存</font></strong></p><p><font face="楷体_GB2312" color="#ff3300" size="4">易瑞沙能使病人吸收胸腔积液或者心包积液的，我爸爸当时服用的时候还是有胸腔积液，服用18个月一直维持很好，生活质量都很好。18个月以后出现耐药性，现在主要表现是气喘，气喘引起咳嗽，非常严重。</font></p><p><font face="楷体_GB2312"><font color="#ff3300" size="4">不知道您爸爸是否出现耐药性？好像症状比较相似，主要表现就是胸水引起的气喘和咳嗽。</font></font></p><p><font face="楷体_GB2312" color="#ff3300" size="4">我爸爸服用易瑞沙期间一直服用中药，还食用雪蛤、西洋参、铁皮枫斗等提高免疫力的东西，我买了蟾蜍皮，但是不敢给他服用，我看到有关报道说有剧毒，会有生命危险。</font></p><p><font face="楷体_GB2312"><font color="#ff3300" size="4">如果你父亲病情和我父亲差不多，请多和我联系，我的QQ: 4708999</font></font></p><p><font face="楷体_GB2312" color="#ff3300" size="4">我爸爸现在已经开始服用二氯乙酸钠，效果好象不是很明显，气喘还是无法控制，还出现疲惫的感觉，望多交流。</font></p>

阡陌

<font face="楷体_GB2312" color="#ff3300" size="4">5、易瑞沙能否使病人吸收胸腔积液或者心包积液，答案是不能吸收，我也是接受易瑞沙，吉非替尼的患者，和我再一起接受治疗的一个人她也是心包积液，吃3个疗程后就转化疗了。</font>